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REPLY LETTER
Reply letter re: “Mass psychogenic illness following HPV immunization in Carmen de
Bolivar, Colombia”
C. Simasa, N. Munozb, L. Arregocesa, and H. J. Larsona
aLondon School of Hygiene and Tropical Medicine, London, UK; bEmeritus Professor at the Cancer Institute of Colombia, International
Epidemiological Association, Colombia
We are replying to the Letter to the Editor1 in reply to our
case report, “Mass psychogenic illness following HPV immu-
nization in Carmen de Bolivar, Colombia.”2
While we appreciate the perspective presented, we believe
that the author is not fully aware of the robust evidence
regarding safety and effectiveness of HPV immunization.
While the author does not refute the psychogenic nature of
adverse events following immunization, he/she calls for ‘open-
ness to uncertainty’. It is unclear to us whether the suggestion
to “maintain uncertainty” implies that we should disregard
the body of available evidence and instead conclude there is
still uncertainty about the events and their causal links to
vaccination? The latest data available on the safety and effec-
tiveness of the HPV vaccine has continued to narrow the
uncertainty, and given the extent of our compiled knowledge,
any new results are unlikely to be very different from what we
have until now observed.
Again, we appreciate and recognize that the nature of science
and research should always be open to new discovery and find-
ings, but we are concerned that by emphasizing the uncertainty
we will undermine the robust evidence which is currently avail-
able. We include below a number of the references and some
extracts and comment on particular excerpts from this letter.
Evidence concerning effectiveness
A significant reduction in the prevalence rates of high grade
histologically confirmed cervical abnormalities (CIN2+) * diag-
nosed in Australian HPV-vaccinated women, between
2000–2014.3 In addition, Around 93% reduction of Genital
Warts in vaccinated women and heterosexual men, non-vacci-
nated in Melbourne, Australia,4,5 and an 8-fold reduction of
Juvenile Onset Recurrent Respiratory Papillomatosis (JORRP)
in children born to HPV-vaccinated mothers in Australia
between 2012 and 20166 A preliminary study has shown
a reduction of invasive cervical cancer in HPV-vaccinated
women in Finland.7
Evidence concerning safety
The most recent paper on safety shows that the risk-benefit
profile for HPV vaccines remains highly favourable.8 The
results of that study concur with that of the recent WHO
position paper9 and the most recent GACVS report.10
The GACVS has met on seven occasions since 2007 to
discuss the safety of the HPV vaccine and have assessed con-
cerns related to anaphylaxis, syncope, mass psychogenic ill-
ness, AID including GBS and MS, VTE, CRPS and POTS. The
GACVS ‘‘considers HPV vaccines to be extremely safe’’, and
reports have been consistently reassuring with no new AEs of
concern identified in the 2017 report based on many large,
high-quality studies and recent data.
Regarding the statement ”While the intention is not to
argue against the case correspondence to a clear example of
mass psychogenic illness, it is interesting that the possible role
of vaccination was not comprehensively discussed when facts
did indicate that it influenced the event.” The possible role of
vaccination in the MPI event was repeatedly mentioned in our
paper, despite us not including the results of the case-control
study. In our discussion section, for example, we state that
although the symptoms being experienced by the school girls
did not have a biological relationship with the HPV vaccine,
they were, in fact, a mass psychogenic reaction provoked by
anxiety and perceptions of risk following the HPV
vaccination.
Concerning the concluding paragraph: ”In conclusion,
given that vaccines against HPV are still under rigorous
scientific research, and more accurate data regarding their
effectiveness and safety is expected within the next few
years, the best position from a strictly scientific standpoint,
is to maintain uncertainty: the ability to be astonished by new
discoveries”. We believe that as post marketing monitoring of
the HPV vaccines continues, there is already solid data show-
ing that these vaccines are safe and effective.
Our publication also adds to the current knowledge around
MPI by recognising that social media has come into the mix
of population characteristics and the sociocultural environ-
ment. The possible association between immunisation and
episodes of MPI cannot be used against routine immunisation
in the same way children cannot be forbidden to attend school
because of the Coca-Cola incident described in our paper.
A better understanding of the context where vaccines pro-
grams are implemented enhance their acceptance and reduces
the risk of events such as MPI.
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